A T cell-costimulation pathway can be combined with an immune checkpoint axis blockade to achieve sustained antitumor immune responses against advanced cancer.160,161 ICOS (inducible T cell costimulator, also known as CD278) and TNFR superfamily members such as 4–1BB and OX40 are promising targets of therapeutic BsAbs. Here, ICOS is linked to cancer.